Clinical Consultations™: Closing the Gap in Early Identification and Treatment of SMA

Release Date: August 18, 2020
Expiration Date: August 18, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of current and emerging data on the diagnosis and treatment of spinal muscular atrophy (SMA). The importance of early diagnosis and treatment, availability of carrier testing and newborn screening in some states, and current and emerging therapies will be presented in a series of videos featuring expert thought leaders in SMA.

This activity is supported by educational grants from AveXis Inc. and Biogen.

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This activity is intended for OB/GYNs and neurologists, as well as physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of SMA.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Describe new and emerging methods of prenatal and newborn screening for SMA
• Discuss clinical trial evidence of the benefits of early treatment initiation in patients with SMA
• Evaluate the mechanism of action, efficacy, and safety of new and emerging agents for the treatment of SMA

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Nancy L. Kuntz, MD
Attending Physician, Division of Neurology;
Medical Director, Mazza Foundation Neuromuscular Program
Director, Muscular Dystrophy Association Care Center
Ann & Robert H Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures: Grant Research Support: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics, Solid Biosciences; Consultant: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics.

Thomas W. Prior, PhD
Professor, Department of Pathology
Director, Molecular Genetics Laboratory
University Hospitals Center for Human Genetics
Case Western Reserve University
Cleveland, OH

Disclosures: Thomas W. Prior, PhD, has no relevant financial relationships with commercial interest to disclose.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.